Q2 Holdings, Inc. (NYSE:QTWO) shares moved up 2.97% in last trading session and ended the day at $27.07. QTWO Gross Margin is 44.90% and its has a return on assets of -12.70%. Q2 Holdings, Inc. (NYSE:QTWO) quarterly performance is -7.86%.
On 1st December, Q2 Holdings, Inc. (NYSE:QTWO), a provider of secure, cloud-based virtual banking solutions, announced the acquisition of Des Moines, Iowa-based Social Money, a financial services software company that offers a modern, cloud-based platform that assists financial institutions in their direct digital strategies, best represented in their award-winning SmartyPig product. The addition of Social Money marks Q2’s second acquisition in 2015, and further fuels its development of secure banking platform solutions for community financial institutions across the country. Q2 acquired all of the outstanding interests of Social Money in exchange for $10.6 million cash payable at closing, subject to a customary working capital adjustment.
Kite Realty Group Trust (NYSE:KRG) ended the last trading day at $25.99. Company weekly volatility is calculated as 1.76% and price to cash ratio as 50.36. Kite Realty Group Trust (NYSE:KRG) showed a weekly performance of -1.70%.
-Kite Realty Group Trust (NYSE: KRG) announced that it will release financial results for the quarter ended December 31, 2015, after the market closes on Thursday, February 4th. The Company will conduct a conference call to discuss its financial results the following day, February 5th, at 11:00 a.m. Eastern Time.
On 09 December, Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) shares fell -2.12% and was closed at $5.53. SPPI EPS growth in last 5 year was -8.60%. Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) year to date (YTD) performance is -20.20%.
Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) and Onxeo S.A. jointly announced the results from their Phase 1 combination trial of belinostat (Beleodaq®) with the CHOP (Cyclophosphamide, Hydroxyl-doxorubicin; Vincristine, and Prednisone) chemotherapy regimen as first-line treatment for newly diagnosed peripheral T-cell lymphoma (PTCL). Beleodaq® is a histone deacetylase (HDAC) inhibitor that received accelerated approval by the U.S. Food and Drug Administration (FDA) for the treatment of relapsed or refractory PTCL in July 2014.
Tenax Therapeutics, Inc. (NASDAQ:TENX) shares fell -1.25% in last trading session and ended the day at $3.16. TENX has a return on assets of -17.80%. Tenax Therapeutics, Inc. (NASDAQ:TENX) quarterly performance is -12.71%.
Tenax Therapeutics, Inc. (NASDAQ: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market, announced that the Company will host a conference call and live audio webcast on Tuesday, December 15, 2015, at 8:30 a.m. ET to provide a corporate update and discuss financial results for the second quarter fiscal year 2016 ended October 31, 2015.
Repligen Corporation (NASDAQ:RGEN) caters to the Healthcare space. It has a net profit margin of 11.00% and weekly performance is -3.82%. On the last day of trading company shares ended up at $27.44. Repligen Corporation (NASDAQ:RGEN) distance from 50-day simple moving average (SMA50) is 1.33%.
Jefferies Group lowered shares of Repligen Corporation (NASDAQ:RGEN) from a buy rating to a hold rating in a report published on Friday, The Fly reports.
Leave a Reply